Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wim Wuyts

Showing results (71-80 of 135) with videos related to

Pageof 14
Sort By:
Chronic Respiratory Disease|March 21, 2024
Physical activity coaching in patients with interstitial lung diseases: A randomized controlled trialSofie Breuls, Tamara Zlamalova, Katerina Raisova, et al.
Respiration; International Review of Thoracic Diseases|July 20, 2018
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary FibrosisPaolo Spagnolo, Michael Kreuter, Toby M Maher, et al.
American Journal of Human Genetics|June 15, 2007
Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosaFrauke Coppieters, Bart P Leroy, Diane Beysen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 8, 2007
High incidence of the CFTR mutations 3272-26A-->G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A-->G, E588V, and 1671insTATCA)Katrien Storm, Els Moens, Lieve Vits, et al.
Advances in Therapy|November 6, 2020
Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus StudyJesper Rømhild Davidsen, Jelle Miedema, Wim Wuyts, et al.
The Journal of Bone and Joint Surgery. American Volume|January 20, 2012
Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of "protective" and "risk" factorsElena Pedrini, Ivy Jennes, Morena Tremosini, et al.
BMJ Open Respiratory Research|June 11, 2019
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)Toby M Maher, Michael Kreuter, David J Lederer, et al.
The Lancet. Respiratory Medicine|April 7, 2016
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysisMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 26, 2020
Desquamative interstitial pneumonia: a systematic review of its features and outcomesMerel E Hellemons, Catharina C Moor, Jan von der Thüsen, et al.
The Lancet. Respiratory Medicine|May 25, 2018
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trialToby M Maher, Ellen M van der Aar, Olivier Van de Steen, et al.
Pageof 14

Showing results (71-80 of 135) with videos related to

Sort By:
Pageof 14
Chronic Respiratory Disease|March 21, 2024
Physical activity coaching in patients with interstitial lung diseases: A randomized controlled trialSofie Breuls, Tamara Zlamalova, Katerina Raisova, et al.
Respiration; International Review of Thoracic Diseases|July 20, 2018
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary FibrosisPaolo Spagnolo, Michael Kreuter, Toby M Maher, et al.
American Journal of Human Genetics|June 15, 2007
Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosaFrauke Coppieters, Bart P Leroy, Diane Beysen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 8, 2007
High incidence of the CFTR mutations 3272-26A-->G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A-->G, E588V, and 1671insTATCA)Katrien Storm, Els Moens, Lieve Vits, et al.
Advances in Therapy|November 6, 2020
Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus StudyJesper Rømhild Davidsen, Jelle Miedema, Wim Wuyts, et al.
The Journal of Bone and Joint Surgery. American Volume|January 20, 2012
Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of "protective" and "risk" factorsElena Pedrini, Ivy Jennes, Morena Tremosini, et al.
BMJ Open Respiratory Research|June 11, 2019
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)Toby M Maher, Michael Kreuter, David J Lederer, et al.
The Lancet. Respiratory Medicine|April 7, 2016
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysisMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 26, 2020
Desquamative interstitial pneumonia: a systematic review of its features and outcomesMerel E Hellemons, Catharina C Moor, Jan von der Thüsen, et al.
The Lancet. Respiratory Medicine|May 25, 2018
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trialToby M Maher, Ellen M van der Aar, Olivier Van de Steen, et al.
Pageof 14